High-throughput screening compatible cell-based assay for interrogating activated notch signaling

Assay and Drug Development Technologies

Volumn 7, Issue 1, 2009, Pages 68-79

  Hancock, Michael K ^a   Kopp, Leisha ^a   Bi, Kun ^a  

^a INVITROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BORTEZOMIB; CLAVULANIC ACID; DASATINIB; GDC 0941; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; ICG 001; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NOTCH RECEPTOR; PROTEIN SYNTHESIS INHIBITOR; RAPAMYCIN; SORAFENIB; STAUROSPORINE; SUNITINIB; TANESPIMYCIN; TETRACYCLINE; TRICIRIBINE; TRIPTOLIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CELL ASSAY; CELL SURFACE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIGAND BINDING; RECEPTOR BINDING; REPORTER GENE; RNA INTERFERENCE; TRANSACTIVATION; TRANSCRIPTION INITIATION;

BASE SEQUENCE; BETA-LACTAMASES; DATA INTERPRETATION, STATISTICAL; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; HELA CELLS; HUMANS; INDICATORS AND REAGENTS; RECEPTORS, NOTCH; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 65349091309     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2008.173     Document Type: Article

References (50)

1. Ehebauer M, Hayward P, Arias AM: Notch, a universal arbiter of cell fate decisions. Science 2006;314:1414-1415.
2. Ilagan MX, Kopan R: SnapShot: notch signaling pathway. Cell 2007; 128:1246.
3. Nam Y, Sliz P, Pear WS, Aster JC, Blacklow SC: Cooperative assembly of higher-order Notch complexes functions as a switch to induce transcription. Proc Natl Acad Sci U S A 2007;104:2103-2108.
4. Weng AP, Aster JC: Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 2004;14:48-54.
5. Eyler CE, Rich JN: Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008;26:2839-2845.
6. Shih le M, Wang TL: Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-1882.
7. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, et al.: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromo- somal translocations in Tlymphoblastic neoplasms. Cell 1991;66:649-661.
8. th, Silverman LB, Sanchez-lrizarry C, et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-271.
9. Weng AP, Lau A: Notch signaling in T-cell acute lymphoblastic leukemia. Future Oncol 2005;1:511-519.
10. Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD, Blacklow SC, et al.: Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003;23:655-664.
11. Kovall RA, Hendrickson WA: Crystal structure of the nuclear effector of Notch signaling, CSL, bound to DNA. EMBO J 2004;23:3441-3451.
12. Nam Y, Sliz P, Song L, Aster JC, Blacklow SC: Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 2006;124:973-983.
13. Nam Y, Weng AP, Aster JC, Blacklow SC: Structural requirements for assembly of the CSL-intracellular Notch1-Mastermind-like 1 transcriptional activation complex. J Biol Chem 2003;278:21232-21239.
14. Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, Feng L, et al.: Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 1998;279:84-88.
15. Eguchi M, Nguyen C, Lee SC, Kahn M: ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med Chem 2005;1:467-472.
16. Schroeter EH, Kisslinger JA, Kopan R: Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998;393:382-386.
17. Hallis TM, Kopp AL, Gibson J, Lebakken CS, Hancock M, Van Den Heuvel- Kramer K, et al.: An improved beta-lactamase reporter assay: multiplexing with a cytotoxicity readout for enhanced accuracy of hit identification. J Biomol Screen 2007;12:635-644.
18. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
19. Yao F, Svensjo T, Winkler T, Lu M, Eriksson C, Eriksson E: Tetracycline repres- sor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther 1998;9:1939-1950.
20. Lu FM, Lux SE: Constitutively active human Notch1 binds to the transcription factor CBF1 and stimulates transcription through a promoter containing a CBF1-responsive element. Proc Natl Acad Sci U S A 1996;93:5663-5667.
21. Yu H, Zhao X, Huang S, Jian L, Qian G, Ge S: Blocking Notch1 signaling by RNA interference can induce growth inhibition in HeLa cells. Int J Gynecol Cancer 2007;17:511-516.
22. Yu H, Huang SL, Zhao XP, Lu J, Qian GX, Ge SF: Effect of CRE-dependent RNA interference targeting Notch1 on proliferation of cervical cancer cell line HeLa. AiZheng 2007;26:148-153.
23. Yao J, Duan L, Fan M, Yuan J, Wu X: Notch1 induces cell cycle arrest and apoptosis in human cervical cancer cells: involvement of nuclear factor kappa B inhibition. Int J Gynecol Cancer 2007;17:502-510.
24. Wang L, Qin H, Chen B, Xin X, Li J, Han H: Overexpressed active Notch1 induces cell growth arrest of HeLa cervical carcinoma cells. Int J Gynecol Cancer 2007;17:1283-1292.
25. Maliekal TT, Bajaj J, Giri V, Subramanyam D, Krishna S: The role of Notch signaling in human cervical cancer: implications for solid tumors. Oncogene 2008;27:5110-5114.
26. Oswald F, Kostezka U, Astrahantseff K, Bourteele S, Dillinger K, Zechner U, et al.: SHARP is a novel component of the Notch/RBP-Jkappa signalling pathway. EMBO J 2002;21:5417-5426.
27. Oswald F, Winkler M, Cao Y, Astrahantseff K, Bourteele S, Knochel W, et al.: RBP-Jkappa/SHARP recruits CtlP/CtBP corepressors to silence Notch target genes. Mol Cell Biol 2005;25:10379-10390.
28. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, et al.: Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. JNeurochem 2001;76:173-181.
29. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE Jr, et al.: Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem 2000;275:34086-34091.
30. Leuenroth SJ, Crews CM: Triptolide-induced transcriptional arrest is associated with changes in nuclear substructure. Cancer Res 2008;68:5257-5266.
31. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622.
32. Stockhausen MT, Sjolund J, Manetopoulos C, Axelson H: Effects of the his- tone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer 2005;92:751-759.
33. Kao HY, Ordentlich P, Koyano-Nakagawa N, Tang Z, Downes M, Kintner CR, et al.: A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev 1998;12:2269-2277.
34. Barginear MF, Van Poznak C, Rosen N, Modi S, Hudis CA, Budman DR: The heat shock protein 90 chaperone complex: an evolving therapeutic target. Curr Cancer Drug Targets 2008;8:522-532.
35. Dotto GP: Notch tumor suppressor function. Oncogene 2008;27:5115-5123.
36. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, et al.: Small molecule blockade of transcriptional coactivation of the hypoxia- inducible factor pathway. Cancer Cell 2004;6:33-43.
37. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, et al.: Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000;406:1005-1009.
38. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, et al.: A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 2004;101:12682-12687.
39. Oswald F, Tauber B, Dobner T, Bourteele S, Kostezka U, Adler G, et al.: p300 acts as a transcriptional coactivator for mammalian Notch-1. Mol Cell Biol 2001;21:7761-7774.
40. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al.: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-132.
41. Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, et al.: PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 2008;22:1698-1706.
42. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ: Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007;110:278-286.
43. Mungamuri SK, Yang X, Thor AD, Somasundaram K: Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006;66:4715-4724.
44. Nair P, Somasundaram K, Krishna S: Activated Notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a PI3K-PKB/Akt-dependent pathway. J Virol 2003;77:7106-7112.
45. Palomero T, Dominguez M, Ferrando AA: The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 2008;7:965-970.
46. Calzavara E, Chiaramonte R, Cesana D, Basile A, Sherbet GV, Comi P: Reciprocal regulation of Notch and PI3K/Akt signalling in T-ALL cells in vitro. J Cell Biochem 2008;103:1405-1412.
47. Song J, Park S, Kim M, Shin I: Down-regulation of Notch-dependent transcription by Akt in vitro. FEBS Lett 2008;582:1693-1699.
48. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, et al.: The identification of 2-(1 H-indazol-4-yl)-6-(4-methanesulfonyl- piperazin-1-ylmethyl)- 4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51:5522-5532.
49. Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ: Targeting the phosphati- dylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs 2005;6:1250-1258.
50. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, et al.: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-433.